



August 14, 2017

✓ **BSE Limited,**  
Department of Corporate Services,  
P. J. Towers, Dalal Street,  
Mumbai Samachar Marg,  
**MUMBAI - 400 001.**

**The National Stock Exchange of India Ltd.,**  
Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
**MUMBAI - 400 051.**

Dear Sir/Madam,

**Sub: Disclosure pursuant to Regulation 30 of the SEBI**  
**(Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Enclosed is a Press Release as regards receipt by the Company and its alliance partner, Natco, the final ANDA approval from USFDA for Lanthanum Carbonate Chewable Tablets 500 mg (base), 750 mg (base), and 1000 mg (base), which are generic equivalents of Shire Development LLC's Fosrenol Chewable Tablets 500 mg, 750 mg and 1000 mg. The product, as the first generic, will be launched shortly.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

Yours faithfully,  
For **LUPIN LIMITED**

  
CAES 119730



**R. V. SATAM**  
**COMPANY SECRETARY**

Encl.: a.a.



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPC IN

## Lupin's alliance partner Natco receives FDA approval for generic Fosrenol Chewable Tablets

**Mumbai, August 14, 2017:** Pharma major Lupin Limited (Lupin) and Natco announced the final ANDA approval of Lanthanum Carbonate Chewable Tablets 500 mg (base), 750 mg (base), and 1000 mg (base) from the United States Food and Drug Administration (FDA). The product, as the first generic, will be launched shortly.

Natco's Lanthanum Carbonate Chewable Tablets 500 mg (base), 750 mg (base), and 1000 mg (base) are generic equivalents of Shire Development LLC's Fosrenol Chewable Tablets 500 mg, 750 mg and 1000 mg. Lanthanum Carbonate Chewable Tablets 500 mg (base), 750 mg (base), and 1000 mg (base) are indicated to reduce serum phosphate in patients with end stage renal disease (ESRD).

Fosrenol Chewable Tablets has US sales of USD 122.4 million (IMS MAT June 2017). Lupin and Natco had entered into an agreement on September 01, 2008 to jointly commercialize generic equivalents of Fosrenol Chewable Tablets.

Commenting on the approval, **Mr Nilesh Gupta, Managing Director, Lupin** said, *"We are very happy to finally be able to launch Lanthanum Carbonate Chewable Tablets in partnership with Natco. Lupin's proven IP capabilities, marketing reach and expertise coupled with Natco's solid development and manufacturing abilities make a great combination"*.

### About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 7<sup>th</sup> and 6<sup>th</sup> largest generics pharmaceutical company by market capitalization (June 30<sup>th</sup>, 2017, Bloomberg) and revenues (March 31<sup>st</sup>, 2017, Bloomberg) respectively. The Company is the 4<sup>th</sup> largest pharmaceutical player in the US by prescriptions (Quintiles IMS MAT March 2017); 2<sup>nd</sup> largest Indian pharmaceutical company by global revenues (March 31<sup>st</sup>, 2017, Bloomberg); 6<sup>th</sup> largest generic pharmaceutical player in Japan and 6<sup>th</sup> largest company in Indian Pharmaceutical Market (Quintiles IMS MAT June 2017).

For the financial year ended 31<sup>st</sup> March, 2017, Lupin's Consolidated sales and Net profit stood at Rs. 171,198 million (USD 2.55 billion) and Rs. 25,575 million (USD 381 million) respectively. Please visit <http://www.lupin.com> for more information. You could also follow us on Twitter - [www.twitter.com/lupinlimited](http://www.twitter.com/lupinlimited)

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

*Press Release*



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPC IN

**For further information or queries please contact –**

**For Lupin**

Pooja Thakran

VP – Corporate Communications

Ph: +91-22-66402531 / 8291013225

Email: [poojathakran@lupin.com](mailto:poojathakran@lupin.com)

Or

Arvind Bothra

Head – Investor Relations and M&A

Ph: +91-22-66402137

Email: [arvindbothra@lupin.com](mailto:arvindbothra@lupin.com)

**\*Safe Harbor Statement**

*Fosrenol® is a registered trademark of Shire International Licensing BV.*